false
0000948320
0000948320
2023-12-11
2023-12-11
0000948320
LFMD:CommonStockParValueMember
2023-12-11
2023-12-11
0000948320
LFMD:SeriesCumulativeMember
2023-12-11
2023-12-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities and Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 11, 2023
LIFEMD,
INC.
(Exact
name of Registrant as specified in its charter)
Delaware |
|
001-39785 |
|
76-0238453 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
800
Third Avenue, Suite 2800
New
York, NY 10022
(Address
of principal executive offices, including zip code)
(866)
351-5907
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:
☐ |
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.01 per share
|
|
LFMD |
|
The
Nasdaq Global Market |
Series
A Cumulative Perpetual Preferred Stock, par value $0.0001 per share
|
|
LFMDP |
|
The
Nasdaq Global Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
3.02 Unregistered Sales of Equity Securities.
Medifast
Collaboration and Private Placement
On
December 11, 2023, LifeMD, Inc., (the “Company”) entered into a collaboration with Medifast, Inc. through and with
certain of its wholly-owned subsidiaries (“Medifast”) (collectively, the “Parties”). Pursuant to certain
agreements between the Parties, Medifast has agreed to pay to the Company the amount of $10 million to support the collaboration,
funding enhancements to the Company platform, operations and supporting infrastructure, of which $5 million was paid at the closing on
December 12, 2023, and the remainder is to be paid in two $2.5 million installments on March 31, 2024 and June 30, 2024 (or earlier
upon the Company’s achievement of certain program milestones). These agreements contain customary representations, warranties,
and other obligations of the Parties.
In
addition, in connection with the collaboration, on December 11, 2023, the Company entered into a Stock Purchase Agreement with
Medifast’s wholly-owned subsidiary Jason Pharmaceuticals, Inc. (the “Purchaser”), whereby the Company issued 1,224,425
shares of its common stock, par value $0.01 per share, in a private placement (the “Private Placement”) at a purchase price
of $8.1671 per share, for aggregate proceeds of approximately $10,000,000. Also therein, the Company granted the Purchaser the right,
for a period contemporaneous with the ongoing collaboration, to appoint one non-voting observer to the Board of Directors of the Company,
entitled to attend Board meetings. The Private Placement closed on December 12, 2023.
Contemporaneously,
the Company and the Purchaser entered into a Registration Rights Agreement, dated December 11, 2023 (the “Registration Rights Agreement”),
under which the Company, upon demand by Medifast, will register the shares of common stock sold thereunder.
The
issuance of shares of Common Stock in the Private Placement described above were made in reliance on the exemption from registration
afforded under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and/or Rule 506 of
Regulation D under the Securities Act.
Cleared Purchase Agreement
As
previously disclosed, on January 11, 2022, the Company entered into a Stock Purchase Agreement (the “Cleared Purchase Agreement),
as amended on February 4, 2003 (the “First Amendment”), by and among the Company, Cleared Technologies, PBC, a
Delaware public benefit corporation (“Cleared”) and the stockholders of Cleared identified therein (the “Sellers”).
On October 17, 2023, the Company issued 117,583 shares of its common stock related to the fourth of five quarterly installment
payments due to the Sellers under the Cleared Purchase Agreement. The First Amendment, among other things, reduced the total purchase
price for Cleared’s stock by $250 thousand to a total of $3.67 million, of which $460 thousand was paid at closing,
with the remaining amount to be paid in the five quarterly installments beginning on or before February 6, 2023 and ending January
15, 2024.
The
issuances of shares of the Company’s common stock pursuant to the First Amendment described above were made in reliance
on the exemption from registration afforded under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D under the Securities
Act.
Stock
Awards and Options
In
the fourth quarter of 2023, through the date of this report, the Company has issued 526,125 shares of its common stock to its
employees related to vested restricted stock units (“RSUs”) and restricted stock awards (“RSAs”) granted under
its 2020 Equity and Incentive Plan and amendments thereto (the “Plan”). In the same period, the
Company has issued 37,500 shares of its common stock on the exercise of stock options that were granted under the Plan.
The
issuances of shares pursuant to the RSUs, RSAs, and stock options identified above were not registered under the Securities Act of 1933,
as amended. Such issuances were made in reliance upon the exemption from registration provided by Section 4(a)(2) under the Securities
Act and/or Rule 506 of Regulation D under the Securities Act.
Item
7.01 Regulation FD Disclosure.
On
December 13, 2023, the Company issued a press release, attached as Exhibit 99.1 to this Current Report on Form 8-K, announcing the collaboration
with Medifast, the Private Placement and related transactions.
The
information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such filing.
Item
8.01 Other Events.
The
information related to the Medifast collaboration and Private Placement disclosed under Item 3.02 of this Current Report on Form 8-K
is incorporated by reference into this Item 8.01 to the extent required herein.
Item
9.01. Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
LIFEMD,
INC. |
|
|
|
|
Dated: |
December
13, 2023 |
By: |
/s/
Eric Yecies |
|
|
|
Eric
Yecies |
|
|
|
Chief
Legal Officer and General Counsel |
Exhibit
99.1
LifeMD
and Medifast Partner to Offer Transformative Weight Management Solution
Collaboration
will integrate LifeMD’s telehealth platform and GLP-1 offering for medically qualified patients with OPTAVIA Coach-guided,
healthy lifestyle solution
Medifast
has invested $20 million, including a $10 million payment in support of the collaboration and a $10 million purchase of LifeMD common
stock
Conference
call to discuss LifeMD and Medifast collaboration begins at 10:00 AM EST today
NEW
YORK, Dec. 13, 2023 – LifeMD, Inc.™ (Nasdaq: LFMD), a leading provider of virtual primary care services, today
announced a strategic alliance with Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided
lifestyle solution OPTAVIA®. Under the terms of the agreement, Medifast will utilize LifeMD’s virtual
care technology platform to provide OPTAVIA Clients access to a clinically supported weight management program, including GLP-1
medications. This collaboration further establishes LifeMD in a market that is projected to reach $100 billion by 2030.1 In
addition, LifeMD will have the ability to offer its patients an independent OPTAVIA Coach and other lifestyle support services
as part of its weight management program.
This
collaboration is intended to create a comprehensive, accessible, and coordinated approach to combating the escalating obesity public
health crisis. By blending LifeMD’s and Medifast’s best-in-class capabilities, the collaboration uniquely offers clinical
care complemented by one-on-one OPTAVIA Coach support, clinically proven plans and scientifically developed products, a proprietary
Habits of Health® Transformational System, as well as community support, delivering a complete solution for effective weight management.
As
part of the agreement, Medifast has invested $20 million into LifeMD, including $10 million in contributions to support the collaboration,
funding enhancements to the LifeMD platform, operations and supporting infrastructure, and a $10 million purchase of LifeMD’s common
stock.
“Combining
lifestyle programs and individualized support with top-tier medical care and prescription therapeutics, like GLP-1 medications, is crucial
for improving and sustaining metabolic health outcomes,” said Justin Schreiber, Chairman and CEO of LifeMD. “Medifast’s
proven coaching model and its established OPTAVIA brand is tightly aligned with LifeMD’s innovative virtual care platform
and network of affiliated clinicians. This synergy is not just complementary; it significantly amplifies LifeMD’s impact in the
weight loss sector. With Medifast’s extensive client base and our advanced virtual care services, we believe that together we are
exceptionally positioned to redefine the weight management industry.”
Medifast
and LifeMD agreed to collaborate following a successful pilot program focused on providing personalized support centered on holistic
health rather than weight loss alone. A recent Medifast-commissioned survey revealed that over 40% of consumers with a BMI greater than
27 are interested in prescription weight-loss medication, with even higher interest among those needing to lose more than 35 pounds.2
LifeMD’s robust technology platform, along with its clinician-driven model – including providers licensed across all
50 states – is uniquely suited to support Medifast’s position as a leader in the U.S. weight management industry.
“This
is a pivotal moment for our business as we take the next step in an aggressive transformation to drive growth in this evolving health
and wellness landscape,” said Dan Chard, Chairman and CEO of Medifast. “Millions of people are seeking a solution that I
believe we are uniquely positioned to provide. Together, Medifast and LifeMD expect to offer a comprehensive health offering starting
with weight management, built around a powerful model of support that includes an independent OPTAVIA Coach and a board-certified
affiliated clinician. Both companies have a long-standing scientific and clinical heritage and share a commitment to helping people make
living a healthy lifestyle second nature.”
Medifast
is known for its habit-based and coach-guided lifestyle solution, OPTAVIA, which provides a simple yet comprehensive approach
to help achieve lasting optimal health and wellbeing. OPTAVIA offers clinically proven plans, scientifically developed products
and a framework for habit creation reinforced by 47,100 active earning coaches,3 about 90% of whom started as customers, and
community support. As a physician-founded company with a 40+ year history, Medifast is a leader in the U.S. weight management industry
and has impacted more than 3 million lives to date.
Conference
Call
LifeMD
and Medifast management will hold a conference call to discuss this transaction and answer questions today beginning at 10:00 AM EST.
The call will be broadcast live over the Internet, hosted on the Investor Relations section of LifeMD’s investor website at www.ir.lifemd.com
or directly here and will be archived online and available through March 13, 2024. In addition, listeners may dial (877) 451-6152
to join via telephone. A telephonic playback will be available from 2:00 PM EST, December 13, 2023, through December 20, 2023. Participants
can dial (844) 512-2921 and enter access code 13743024 to hear the playback. Slides describing the announcement are available at www.ir.lifemd.com.
About
LifeMD, Inc.
LifeMD
is a leading provider of virtual primary care. LifeMD offers telemedicine, laboratory and pharmacy services, and specialized treatment
across more than 200 conditions, including primary care, men’s health, women’s health, allergy & asthma, and dermatology.
Leveraging a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a U.S.-based patient
care center, LifeMD is elevating healthcare by increasing access to top-notch and affordable care. For more information, please visit
LifeMD.com.
Cautionary
Note Regarding Forward-Looking Statements
This
news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section
21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform
Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,”
“expect,” “anticipate,” “project,” “should,” “plan,” “will,”
“may,” “intend,” “estimate,” predict,” “continue,” and “potential,”
or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking
statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance
and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving
regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the
effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking
statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations,
beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy,
and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements
relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult
to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may
differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited
to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to,
our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results,
performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative
of our actual results, performance, or financial condition in subsequent periods.
Any
forward-looking statement made in the news release is based on information currently available to us as of the date on which this release
is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future
events, or otherwise, except as may be required under applicable law or regulation.
Company
Contact
Marc
Benathen, Chief Financial Officer
marc@lifemd.com
Media
Contact
Jessica
Friedeman, Chief Marketing Officer
press@lifemd.com
1
Terence Flynn, Framing the Mounjaro bull case in diabesity, Morgan Stanley Research, September,
14, 2023
2
Independent research commissioned by Medifast, June 2023
3
As publicly announced for Q3 2023
v3.23.3
Cover
|
Dec. 11, 2023 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Dec. 11, 2023
|
Entity File Number |
001-39785
|
Entity Registrant Name |
LIFEMD,
INC.
|
Entity Central Index Key |
0000948320
|
Entity Tax Identification Number |
76-0238453
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
800
Third Avenue
|
Entity Address, Address Line Two |
Suite 2800
|
Entity Address, City or Town |
New
York
|
Entity Address, State or Province |
NY
|
Entity Address, Postal Zip Code |
10022
|
City Area Code |
(866)
|
Local Phone Number |
351-5907
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
false
|
Common Stock Par Value [Member] |
|
Title of 12(b) Security |
Common
Stock, par value $0.01 per share
|
Trading Symbol |
LFMD
|
Security Exchange Name |
NASDAQ
|
Series Cumulative [Member] |
|
Title of 12(b) Security |
Series
A Cumulative Perpetual Preferred Stock, par value $0.0001 per share
|
Trading Symbol |
LFMDP
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=LFMD_CommonStockParValueMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=LFMD_SeriesCumulativeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
LifeMD (NASDAQ:LFMDP)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
LifeMD (NASDAQ:LFMDP)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024